Melanie Senior
It has got to be one of the most exciting times for any biotech company: preparing to finally launch a...
With perhaps little over a year to go before it files its NDA for hepatitis C hopeful telaprevir, Vertex is gearing up for its transition to a commercially focused company. New CEO Matt Emmens talks to IN VIVO about the financial and cultural challenges of building a commercial organization to match Vertex's highly productive R&D.
Melanie Senior
It has got to be one of the most exciting times for any biotech company: preparing to finally launch a...